New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01773915

Enrollment

Registered

2013-01-23

Start date

2012-12-31

Completion date

2014-06-30

Last updated

2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Late Onset

Brief summary

Alzheimer's disease (AD) is the most common neurodegenerative disorder afflicting the elderly. Currently, some biochemical tests performed on Cerebrospinal Fluid (CSF) samples have demonstrated to discriminate to some extend between AD and non-AD individuals based on the levels of tau, phospho-tau or Aβ42. We aim to investigate newly identified proteins whose levels increase during the Braak Stages of AD that are accessible in other body fluids such as blood, urine or saliva. The detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the AD pathology.

Detailed description

We do not desire to provide a more extensive description

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- mild to moderate AD

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.	Up to 1 year	Protein levels will be measured by classical immunoblotting blot analysis and quantified; Classical statistical analyses will be performed in order to detect any significant differences.

Countries

Belgium

Contacts

Primary ContactJos Tournoy

jos.tournoy@uzleuven.be+3216342640

Outcome results